ACS network-based implementation of therapeutic hypothermia for the treatment of comatose out-of-hospital cardiac arrest survivors improves clinical outcomes: the first European experience

Table 5 Comparison of the occurrence of safety end points in patients treated with and without mild therapeutic hypothermia

	Patients undergoing MTH procedure	Control group	p
	(n = 32)	(n = 33)
Definite stent thrombosis*	0 (0%)	0 (0%)	ns
Probable stent thrombosis*	0 (0%)	2 (7.4%)	ns
Pneumonia	19 (59.4%)	19 (57.6%)	ns
Positive blood culture	12 (37.5%)	11 (33.3%)	ns
Bleeding of any severity	8 (25.0%)	5 (15.2%)	ns
Red blood cell transfusion	4 (12.5%)	2 (6.1%)	ns
Rhythm and conductions disorders:			ns
Atrial fibrillation	6 (18.8%)	7 (21.2%)	ns
Ventricular tachycardia	3 (9.4%)	1 (3.0%)	ns
Clinically relevant bradycardia	3 (9.4%)	1 (3.0%)	ns

* The percentage refers to the number of patients treated with percutaneous coronary intervention in the group. MTH Mild therapeutic hypothermia.

ISSN: 1757-7241